Ann: Opthea announces A$80m Capital raise, page-44

The information released with the capital raising is very informative.

I have a theory regarding the statement on slide 27 from the OPT presentation: "Masked data from patients that have completed the week 52 visit in the ongoing Phase 3 clinical trials show greater mean BCVA increases from baseline than results with standard of care anti-VEGF-A monotherapy from Opthea’s Phase 2b study."

I think this will speed up the recruitment of participants into the trial as essentially, they are finding the new treatment is working (all subject to the disclaimers given by OPT). Eye specialists will hear about this and be trying to get their patients enrolled in the trials. The opportunity to try something that seemingly works will be now more attractive to some patients who may have been hesitant previously.

This means the trial may reach full enrolment sooner, be concluded earlier and the top line readout can occur earlier, all making the best use of the cash being raised.

I think this is a wonderful opportunity for new and existing shareholders. I own, will participate in the rights issue (and bought some more today), and hold out to the conclusion of the trials.